Published in Lancet on July 03, 2008
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer | NCT00033904
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene (2012) 2.82
The cancer vaccine roller coaster. Nat Biotechnol (2009) 2.26
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Vitespen: a vaccine for renal cancer? Lancet (2008) 1.48
CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun (2011) 1.32
A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol (2009) 1.28
Strategies for cancer vaccine development. J Biomed Biotechnol (2010) 1.26
Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol (2013) 1.19
Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. Cancer Immunol Immunother (2013) 1.19
Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol (2010) 1.16
Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist (2014) 1.11
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs (2009) 1.09
Immunotherapy for renal cell carcinoma. Clin Dev Immunol (2011) 1.02
Immunotherapeutic strategies in kidney cancer--when TKIs are not enough. Nat Rev Clin Oncol (2009) 1.01
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol (2013) 0.98
Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology (2013) 0.95
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res (2009) 0.95
Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother (2013) 0.93
Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res (2014) 0.92
Heat shock proteins: stimulators of innate and acquired immunity. Biomed Res Int (2013) 0.92
Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response. J Biol Chem (2011) 0.92
The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol (2011) 0.91
Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy (2011) 0.90
Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis. J Hematol Oncol (2009) 0.89
Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res (2014) 0.89
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. Hum Vaccin Immunother (2012) 0.88
Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. J Exp Clin Cancer Res (2011) 0.86
Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo. J Immunol (2013) 0.86
Efficient cross-priming of antiviral CD8+ T cells by antigen donor cells is GRP94 independent. J Immunol (2009) 0.84
Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. Onco Targets Ther (2014) 0.83
Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother (2015) 0.83
Primer on tumor immunology and cancer immunotherapy. J Immunother Cancer (2013) 0.82
Cancer immunotherapy products: regulatory aspects in the European Union. Hum Vaccin Immunother (2012) 0.82
Heat shock protein vaccines against glioblastoma: from bench to bedside. J Neurooncol (2015) 0.82
High molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapy. Int J Hyperthermia (2013) 0.81
Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol (2011) 0.80
Clinical efficacy of radical nephrectomy versus nephron-sparing surgery on localized renal cell carcinoma. Eur J Med Res (2014) 0.80
Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj J (2012) 0.80
Immunotherapy of tumors with α2-macroglobulin-antigen complexes pre-formed in vivo. PLoS One (2012) 0.80
Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies. J Transl Med (2011) 0.80
Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol (2010) 0.79
Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol (2012) 0.79
Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis. BMC Cancer (2011) 0.79
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Curr Oncol (2009) 0.78
Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4. Front Oncol (2013) 0.78
Tumor immunotherapy based on tumor-derived heat shock proteins (Review). Oncol Lett (2013) 0.78
Systemic adjuvant therapies in renal cell carcinoma. Oncol Rev (2012) 0.78
Preparation of a heat-shock protein 70-based vaccine from DC-tumor fusion cells. Methods Mol Biol (2011) 0.78
Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein. Cell Mol Immunol (2011) 0.78
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology (2015) 0.77
A role for the heat shock protein-CD91 axis in the initiation of immune responses to tumors. Immunol Res (2011) 0.77
Is cancer vaccination feasible at older age? Exp Gerontol (2014) 0.77
Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2016) 0.77
Does adjuvant vitespen prevent recurrence in patients with locally advanced kidney cancer? Nat Clin Pract Urol (2008) 0.77
Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells. Oncol Rep (2015) 0.76
Identification of chaperones as essential components of the tumor rejection moieties of cancers. Cancer Immun (2012) 0.76
Prophylactic Antitumor Effect of Mixed Heat Shock Proteins/Peptides in Mouse Sarcoma. Chin Med J (Engl) (2015) 0.76
Dendritic-tumor fusion cells derived heat shock protein70-peptide complex has enhanced immunogenicity. PLoS One (2015) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Tumor Vaccines for Malignant Gliomas. Neurotherapeutics (2017) 0.75
Hsp110-mediated enhancement of CD4+ T cell responses to the envelope glycoprotein of members of the family Flaviviridae in vitro does not occur in vivo. Clin Vaccine Immunol (2010) 0.75
State of the art in tumor antigen and biomarker discovery. Cancers (Basel) (2011) 0.75
Specific immunotherapy in renal cancer: a systematic review. Ther Adv Urol (2016) 0.75
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. Oncotarget (2016) 0.75
Phenotypically distinct helper NK cells are required for gp96-mediated anti-tumor immunity. Sci Rep (2016) 0.75
Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with Gastric Cancer. J Cancer (2017) 0.75
[Renal cell carcinoma: recent developments in diagnostics and therapy]. Urologe A (2010) 0.75
History and current state of immunotherapy in glioma and brain metastasis. Ther Adv Med Oncol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Renal cell carcinoma. Lancet (2009) 6.92
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol (2005) 3.49
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol (2013) 3.31
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res (2009) 3.07
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
High prevalence of vitamin D deficiency among pregnant women and their newborns in northern India. Am J Clin Nutr (2005) 2.75
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. Eur Urol (2012) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res (2010) 2.26
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol (2011) 2.17
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. J Clin Oncol (2004) 2.05
Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J (2007) 2.04
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J (2009) 2.00
Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol (2009) 1.96
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol (2004) 1.86
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence. Am J Surg Pathol (2009) 1.84
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol (2010) 1.80
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst (2012) 1.72
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol (2008) 1.70
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int (2012) 1.64
Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol (2003) 1.63
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol (2002) 1.62
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol (2006) 1.61
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol (2010) 1.60
Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol (2009) 1.59
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine (2007) 1.58
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol (2006) 1.56
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst (2008) 1.53
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol (2012) 1.50
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol (2008) 1.49
Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough? Cancer (2008) 1.48
Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol (2004) 1.47
Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology (2010) 1.46
Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med (2007) 1.45
Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health (2007) 1.45
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 1.43